It probably comes as no surprise Theranos, the blood testing technology company once worth billions, is struggling to survive. A new report from the Wall Street Journal says the company had just $200 million cash on hand left at the end of 2016 – a quarter of its $800 million in total funding. According to the Journal’s investor sources, Theranos disclosed that number on a… Read More